Market Place
Sourcing Support
Mdna11 Data to be Presented at Immunotherapy Bridge 2024
27 Nov 2024 //
GLOBENEWSWIRE
Medicenna Presents MDNA11 & Bizaxofusp Data at SNO Annual Meeting
25 Nov 2024 //
GLOBENEWSWIRE
Medicenna Reports Q2 FY 2025 Financial Results, Update
15 Nov 2024 //
GLOBENEWSWIRE
Medicenna Announces Presentations at SNO & SABCS 2024
13 Nov 2024 //
GLOBENEWSWIRE
Medicenna Announces Positive MDNA11 Data with KEYTRUDA® at SITC
11 Nov 2024 //
GLOBENEWSWIRE
Medicenna Presents Anti-PD1-IL-2 BiSKIT Data at 39th SITC
08 Nov 2024 //
GLOBENEWSWIRE
Medicenna To Present Clinical And Preclinical Data At SITC
04 Oct 2024 //
GLOBENEWSWIRE
Medicenna Announces Results of Annual Meeting of Shareholders
26 Sep 2024 //
GLOBENEWSWIRE
Medicenna Presents Preclinical Results At Conference
09 Sep 2024 //
GLOBENEWSWIRE
Medicenna Announces Presentations At Interleukin-2 Therapy Conference
27 Aug 2024 //
GLOBENEWSWIRE
Medicenna Strengthens Board of Directors with Appointment of Karim Lalji
15 Aug 2024 //
GLOBENEWSWIRE
Medicenna Reports Q1 2025 Results And MDNA11 Complete Response
01 Aug 2024 //
GLOBENEWSWIRE
Medicenna Reports Fiscal Year 2024 Financial Results and Operational Highlights
27 Jun 2024 //
GLOBENEWSWIRE
Medicenna Announces EMA Approval of its Clinical Trial Application
26 Jun 2024 //
GLOBENEWSWIRE
Medicenna`s Bizaxofusp Shows Survival Benefit In Recurrent Glioblastoma
03 Jun 2024 //
GLOBENEWSWIRE
Medicenna`s MDNA11 Data At Oncology Forum On Single Agent Activity
31 May 2024 //
GLOBENEWSWIRE
Medicenna Gives MDNA11 ABILITY-1 Update At Sachs Forum
22 May 2024 //
GLOBENEWSWIRE
Medicenna Provides Update on its Presentations at the 2024 ASCO Annual Meeting
13 May 2024 //
GLOBENEWSWIRE
Medicenna Closes CA$20M Investment From RA Capital
30 Apr 2024 //
GLOBENEWSWIRE
Medicenna Announces CA$20M Investment from RA Capital
26 Apr 2024 //
GLOBENEWSWIRE
Medicenna Presents Updated MDNA11 Anti-Tumor Activity Results
10 Apr 2024 //
GLOBENEWSWIRE
Medicenna Updates MDNA11 Data at AACR 2024
09 Apr 2024 //
GLOBENEWSWIRE
Medicenna to Present at the 2024 Bloom Burton & Co. HIC
04 Apr 2024 //
GLOBENEWSWIRE
Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial
06 Mar 2024 //
GLOBENEWSWIRE
Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results
14 Feb 2024 //
GLOBENEWSWIRE
Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11
13 Feb 2024 //
GLOBENEWSWIRE
Medicenna Announces Appointment of New Auditor
12 Jan 2024 //
GLOBENEWSWIRE
Medicenna Commences Enrollment in the Study Combining MDNA11 with Pembrolizumab
09 Jan 2024 //
GLOBENEWSWIRE
Medicenna Extends Period to Exercise Certain Warrants
21 Dec 2023 //
GLOBENEWSWIRE
Medicenna Announces Trading on the OTCQB Under the Symbol MDNAF
19 Dec 2023 //
GLOBENEWSWIRE
Medicenna Announces Compelling Survival Benefit from Phase 2b of Bizaxofusp
17 Nov 2023 //
GLOBENEWSWIRE
Medicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results
14 Nov 2023 //
GLOBENEWSWIRE
Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data
09 Nov 2023 //
GLOBENEWSWIRE
Medicenna Announces Promising Single-Agent Response and Durability of MDNA11
06 Nov 2023 //
GLOBENEWSWIRE
Medicenna Presents Preclinical Data on MDNA113
03 Nov 2023 //
GLOBENEWSWIRE
Medicenna shifts to Toronto state of mind, Nasdaq listing lapses
27 Oct 2023 //
FIERCE BIOTECH
Medicenna Doses First Patient in Phase 2 Portion of Study Evaluating MDNA11
25 Oct 2023 //
GLOBENEWSWIRE
Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer
10 Oct 2023 //
GLOBENEWSWIRE
Medicenna Presents Preclinical MDNA223 BiSKIT Data
03 Oct 2023 //
GLOBENEWSWIRE
Medicenna Announces Results of Annual and Special Meeting of Shareholders
28 Sep 2023 //
GLOBENEWSWIRE
Medicenna to Participate at The H.C. Wainwright 25th Annual Global Conference
06 Sep 2023 //
GLOBENEWSWIRE
Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer
28 Aug 2023 //
GLOBENEWSWIRE
Medicenna Appoints Brent Meadows as Chief Business Officer
14 Aug 2023 //
GLOBENEWSWIRE
Medicenna Commences Monotherapy Dose Expansion in the Phase 1/2 Study
09 Aug 2023 //
GLOBENEWSWIRE
Medicenna Appoints Dr. Arash Yavari as Chair of Development Advisory Committee
08 Aug 2023 //
GLOBENEWSWIRE
Medicenna to Provide Clinical Update from Ph 1/2 ABILITY Study on August 9, 2023
04 Aug 2023 //
GLOBENEWSWIRE
Medicenna Reports First Quarter Fiscal 2024 Financial Results
28 Jul 2023 //
GLOBENEWSWIRE
Medicenna Presents at National Brain Tumor Society`s Research Round Table
25 Jul 2023 //
GLOBENEWSWIRE
Medicenna Extends Period to Exercise Certain Warrants
05 Jul 2023 //
GLOBENEWSWIRE
Medicenna Reports Fiscal Year 2023 Financial Results and Operational Highlights
27 Jun 2023 //
GLOBENEWSWIRE
Medicenna Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement
27 Apr 2023 //
GLOBENEWSWIRE
Medicenna to Present at the 2023 Bloom Burton & Co. Healthcare Conference
18 Apr 2023 //
GLOBENEWSWIRE
Medicenna Presents Preclinical IL-13 Superkine Data at the AACR Annual Meeting
17 Apr 2023 //
GLOBENEWSWIRE
Medicenna Provides Update from Dose Escalation Portion of Ph 1/2 ABILITY Study
30 Mar 2023 //
GLOBENEWSWIRE
Medicenna Announces Upcoming Presentation at the AACR Annual Meeting
15 Mar 2023 //
GLOBENEWSWIRE
Medicenna to Present at the Oppenheimer 33rd Annual Healthcare Conference
02 Mar 2023 //
GLOBENEWSWIRE
Medicenna Establishes At-the-Market Sales Facility
17 Feb 2023 //
GLOBENEWSWIRE
Medicenna Reports Third Quarter Fiscal 2023 Financial Results
07 Feb 2023 //
GLOBENEWSWIRE
Medicenna to Present at the 2023 Guggenheim Oncology Conference
31 Jan 2023 //
GLOBENEWSWIRE
